z-logo
open-access-imgOpen Access
Glycan Nanostructures of Human Coronaviruses
Author(s) -
Wenjie Guo,
Harini Lakshminarayanan,
Alexander Rodriguez-Palacios,
Robert A. Salata,
Kaijin Xu,
Mohamed Shehata Draz
Publication year - 2021
Publication title -
international journal of nanomedicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.245
H-Index - 128
eISSN - 1178-2013
pISSN - 1176-9114
DOI - 10.2147/ijn.s302516
Subject(s) - glycan , coronavirus , glycoprotein , virology , middle east respiratory syndrome coronavirus , virus , biology , covid-19 , disease , medicine , infectious disease (medical specialty) , genetics , pathology
Human coronaviruses present a substantial global disease burden, causing damage to populations' health, economy, and social well-being. Glycans are one of the main structural components of all microbes and organismic structures, including viruses-playing multiple essential roles in virus infection and immunity. Studying and understanding virus glycans at the nanoscale provide new insights into the diagnosis and treatment of viruses. Glycan nanostructures are considered potential targets for molecular diagnosis, antiviral therapeutics, and the development of vaccines. This review article describes glycan nanostructures (eg, glycoproteins and glycolipids) that exist in cells, subcellular structures, and microbes. We detail the structure, characterization, synthesis, and functions of virus glycans. Furthermore, we describe the glycan nanostructures of different human coronaviruses, such as human coronavirus 229E (HCoV-229E), human coronavirus OC43 (HCoV-OC43), severe acute respiratory syndrome-associated coronavirus (SARS-CoV), human coronavirus NL63 (HCoV-NL63), human coronavirus HKU1 (HCoV-HKU1), the Middle East respiratory syndrome-associated coronavirus (MERS-CoV), and how glycan nanotechnology can be useful to prevent and combat human coronaviruses infections, along with possibilities that are not yet explored.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here